Lutetium (177Lu) oxodotreotide for treating unresectable or metastatic neuroendocrine tumours (TA539)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 29 August 2018
Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease (TA449)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 28 June 2017
Cabozantinib for treating advanced neuroendocrine tumours that have progressed after systemic treatment [ID6474]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 21 May 2026
Lutetium oxodotreotide with octreotide for newly diagnosed unresectable or metastatic gastroenteropancreatic neuroendocrine tumours [ID6315]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Lutetium (177Lu) oxodotreotide for treating SSTR-positive advanced or inoperable gastroenteropancreatic neuroendocrine tumours in people 12 to 17 years [TSID12154]Status:Topic prioritisationProgramme:Technology appraisal guidanceExpected publication date: TBC